Efficacy and safety of interferon-free treatment in patients with chronic hepatitis C
Not Applicable
Recruiting
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000037575
- Lead Sponsor
- Osaka university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients treated with contraindicated drug together with direct acting antivirals 2. Patients who were judged inadequate to participate by researchers.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sustained virological response rates at 24weeks after the end of treatment
- Secondary Outcome Measures
Name Time Method factors contributing to sustained virological response appearance of RAS(resistant associated substitutions) occurrence of hepatocellular carcinoma factors associated with occurrence of hepatocellular carcinoma changes in liver fibrosis and liver function life prognosis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie interferon-free treatment efficacy in chronic hepatitis C patients with specific genotypes?
How does interferon-free treatment compare to standard interferon-based regimens in terms of sustained virologic response rates and adverse effects for chronic hepatitis C?
Which biomarkers are most predictive of response to interferon-free treatment in JPRN-UMIN000037575's chronic hepatitis C cohort?
What are the long-term safety outcomes of interferon-free treatment in chronic hepatitis C patients with advanced liver fibrosis?
How do current interferon-free treatment approaches in JPRN-UMIN000037575 compare to direct-acting antiviral agents like sofosbuvir or glecaprevir in terms of virologic clearance and resistance profiles?